Repligen (RGEN) said Tuesday it completed its acquisition of BioLife Solutions (BLFS).
BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock per share, with cash paid in lieu of fractional shares, the company said.
Repligen said the combination will expand its global reach and cell therapy offering, with further details on its impact on the 2026 financial outlook expected at its Q3 earnings call.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.